Crossmark

A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease

Crossref DOI link: https://doi.org/10.1186/s12906-025-04759-4

Published Online: 2025-01-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mighani, Sara

Samimi, Rasoul

Nooshabadi, Mohamadreza Rashidi

Farzam, Seyed Amir

Haghighian, Hossein Khadem

Javadi, Maryam
Funding

Funding for this research was provided by:

Qazvin University of Medical Sciences (IR.QUMS.REC.1400.362)
License Information

Text and Data Mining valid from 2025-01-30

Version of Record valid from 2025-01-30
More Information

Article History

Received: 7 April 2024

Accepted: 14 January 2025

First Online: 30 January 2025

Declarations

:

: The protocol of the study after approving with the ethic committee of Qazvin University of Medical Sciences (ethic code: IR.QUMS.REC.1400.362), Qazvin, Iran, was registered in the Iranian Registry of Clinical Trials website by the IRCT20141025019669N21 code. Informed consent was obtained from all individual participants included in the study.

: Not applicable.

: The authors declare no competing interests.

: The authors state they have no conflict of interest.

Document is current

Any future updates will be listed below